OMGA — Omega Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $125.20m
- $70.66m
- $3.09m
Annual cashflow statement for Omega Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.9 | -29.4 | -68.3 | -103 | -97.4 |
| Depreciation | |||||
| Non-Cash Items | 0.368 | 0.71 | 4.78 | 12.5 | 13.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.1 | 1.46 | 4.5 | -9.88 | -9.37 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -15.7 | -26.1 | -57.6 | -98.5 | -91.5 |
| Capital Expenditures | -0.885 | -1.81 | -1.47 | -1.38 | -2.87 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -38.9 | -16.7 | 50.4 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.885 | -1.81 | -40.4 | -18.1 | 47.5 |
| Financing Cash Flow Items | -0.039 | -0.083 | -0.347 | 0 | -0.288 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 12 | 48.6 | 262 | 0.708 | 41.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.58 | 20.7 | 164 | -116 | -2.17 |